Covance is one of the world's largest and most comprehensive drug development services companies with more than 10,000 employees in 60 countries.
Covance is one of the world's largest and most comprehensive drug development services companies with more than 10,000 employees in 60 countries. Customized and committed to clients large or small, through its discovery, nonclinical, clinical, CMC and commercialization services, Covance has helped pharmaceutical and biotech companies develop one-third of all prescription medicines in the market today.
This is a focused introduction on the Covance CMC development capabilities for small and large molecules.
Small Molecule Chemistry, Manufacturing & Controls Development Services (CMC)
Covance offers a comprehensive and integrated set of CMC Pharmaceutical Development Services, including API development and supply, preformulation and formulation development, analytical and stability, and regulatory documentation services.
Built on the optimal combination of top-five pharma expertise, experience and facilities, and decades of excellent client service record, Covance is committed to helping pharmaceutical companies reduce time in development and improve molecule hit rate.
Biotechnology Services: Large Molecule CMC Analytical and Testing Services
With over 250 different biomolecules successfully supported annually, Covance now offers the most comprehensive biotechnology service in the industry.
Our experience covers a wide range of biomolecules, including recombinant proteins, monoclonal antibodies, vaccines, blood products, gene therapy products and more. Our capabilities include protein analytical chemistry, immunocharacterization, cell banking, biosafety testing, viral clearance, bioassay studies, molecular biology, stability and release, biomanufacturing support and more.
You can choose to work with us on individual projects, milestone-based packages or full drug development solutions, whichever best fit your needs.
Is “right first time, every time” a pipedream for metabolite identification by LC-MS?
March 18th 2025The dream state If we lived in an ideal world, it would be possible to unambiguously identify metabolites using a single analytical experiment. This analytical technique would need to be efficient and easily generate the information needed from a routine assay that is also robust, enabling confident decision-making during drug discovery. At SCIEX, we believe that metabolite identification using the ZenoTOF 7600 system gets close to this dream state.